Assessing Edwards Lifesciences: Insights From 11 Financial Analysts
Portfolio Pulse from Benzinga Insights
Edwards Lifesciences (NYSE:EW) received mixed ratings from 11 financial analysts, with an updated average 12-month price target of $96.45, reflecting a 5.25% increase from the previous target. Analysts' actions include both upgrades and downgrades, with price targets ranging from $85.00 to $105.00. Edwards Lifesciences, a leader in medical devices for structural heart disease, shows strong financial performance with a 9.5% revenue growth rate, a net margin of 22.02%, and an ROE of 5.11%.
May 07, 2024 | 4:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Edwards Lifesciences received mixed analyst ratings, with an updated average 12-month price target of $96.45, indicating a positive outlook. The company's strong financial performance, including a 9.5% revenue growth and a net margin of 22.02%, supports a bullish perspective.
The mixed analyst ratings with a majority leaning towards positive adjustments in price targets suggest a generally optimistic outlook for Edwards Lifesciences. The company's strong financial indicators, such as high revenue growth and net margin, further bolster the case for a potential increase in stock price in the short term. The increase in the average price target by 5.25% reflects growing confidence among analysts, which could influence investor sentiment positively.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100